Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes management
FAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions.
Projectdetails
Introduction
FAIRGLUCOSE proposes a low-cost, sustainable, and self-powered standalone glucose sensing system that relies on the well-known oxidation process of glucose coming from finger prick blood. This system transfers the glucose measurement to a voltage readout through an innovative and extremely simple strategy.
Device Design
In this way, a measurement that typically requires a potentiostat with a microcontroller and a battery is performed here with a minimalistic and battery-less circuit that fits within the footprint of a commercial glucose strip.
Benefits
This design allows for:
- A reduction in device cost
- A decrease in the generation of waste from electrical and electronic equipment (WEEE or e-waste)
By avoiding the cumulative effect of millions of tests and their corresponding batteries performed at remote sites away from adequate recycling infrastructures, the environmental impact is significantly lessened.
Result Interpretation
In order to interpret the result, the strip can be integrated into a card format that translates voltage into level bars accounting for:
- Low glucose indicators
- Normal glucose indicators
- High glucose indicators
This solution could substitute urine strips or be designed into a more sophisticated but still low-cost card containing an NFC chip, allowing the transfer of a numeric result into a cell phone.
Technology Implementation
Both cards could be implemented with state-of-the-art flexible electronics technologies and could be reused infinitely, as energy would always come from the sample.
Target Market
The first targeted market of FAIRGLUCOSE solutions is located in low and middle-income countries, where the cost of current glucometers severely limits the self-monitoring of blood glucose among the population.
Future Prospects
However, in the mid-term, it is likely that the sustainability and affordability of the approach will displace the current glucose players in some market niches of developed countries and generate new applications in the healthcare and agro-food arena.
Conclusion
Thus, FAIRGLUCOSE aims to investigate the commercial feasibility of this disruptive approach and create an innovation roadmap that allows deploying the technology where it can make the most impact.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-5-2022 |
Einddatum | 31-10-2023 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnosticsPRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries. | ERC Proof of... | € 150.000 | 2023 | Details |
Miniaturized flexible batteries for next generation wearable healthcare sensorsFlexiMin aims to develop a flexible, miniaturized battery to power next-gen wearable sensors for continuous biomarker monitoring, enhancing healthcare diagnostics and market readiness. | ERC Proof of... | € 150.000 | 2025 | Details |
Metal-Organic-Framework Kinetic Array for Diabetes DetectionThis project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis. | ERC Proof of... | € 150.000 | 2024 | Details |
Sensor islet organoids (SILORGS) for in vivo identification of anti-diabetic drugsDevelop a non-invasive in vivo imaging platform using sensor islet organoids in mice to assess β-cell function and survival for validating new diabetes treatments. | ERC Proof of... | € 150.000 | 2024 | Details |
Neuromorphic Flexible Electro/chemical Interface for in-Memory Bio-Sensing and Computing.Develop a miniaturized, self-contained biosensing technology using neuromorphic devices for real-time monitoring and classification of neurodegenerative biomarkers in individualized healthcare. | ERC Starting... | € 1.500.000 | 2025 | Details |
self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics
PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.
Miniaturized flexible batteries for next generation wearable healthcare sensors
FlexiMin aims to develop a flexible, miniaturized battery to power next-gen wearable sensors for continuous biomarker monitoring, enhancing healthcare diagnostics and market readiness.
Metal-Organic-Framework Kinetic Array for Diabetes Detection
This project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis.
Sensor islet organoids (SILORGS) for in vivo identification of anti-diabetic drugs
Develop a non-invasive in vivo imaging platform using sensor islet organoids in mice to assess β-cell function and survival for validating new diabetes treatments.
Neuromorphic Flexible Electro/chemical Interface for in-Memory Bio-Sensing and Computing.
Develop a miniaturized, self-contained biosensing technology using neuromorphic devices for real-time monitoring and classification of neurodegenerative biomarkers in individualized healthcare.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scaleDeveloping a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensingGLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications. | EIC Transition | € 2.194.210 | 2022 | Details |
Ontwikkeling betaalbare FBG sensor voor medische toepassingenImagin Motion ontwikkelt een betaalbare FBG sensor voor het verbeteren van medische scans en bestraling door patiëntbeweging te meten. | Mkb-innovati... | € 20.000 | 2021 | Details |
GlucoMoveIQHet project ontwikkelt een subcutane glucosemonitor met hoge nauwkeurigheid en een batterijlevensduur van twee jaar voor betere diabeteszorg. | Mkb-innovati... | € 20.000 | 2024 | Details |
Minimally invasive reliAble Glucose monitoring in Intensive CareGlucoSet aims to develop a novel continuous glucose monitor for ICU patients to improve glucose control, enhance patient outcomes, and achieve CE-mark approval within 25 months. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensing
GLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications.
Ontwikkeling betaalbare FBG sensor voor medische toepassingen
Imagin Motion ontwikkelt een betaalbare FBG sensor voor het verbeteren van medische scans en bestraling door patiëntbeweging te meten.
GlucoMoveIQ
Het project ontwikkelt een subcutane glucosemonitor met hoge nauwkeurigheid en een batterijlevensduur van twee jaar voor betere diabeteszorg.
Minimally invasive reliAble Glucose monitoring in Intensive Care
GlucoSet aims to develop a novel continuous glucose monitor for ICU patients to improve glucose control, enhance patient outcomes, and achieve CE-mark approval within 25 months.